Related Experiment Video

Updated: May 12, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)

Margaret T May1, Suzanne M Ingle2, Dominique Costagliola2

  • 1School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F-75013, Paris, France; INSERM, UMR_S 943, F-75013, Paris, France; AP-HP, Hôpital Pitié-Salpétrière, Service des maladies infectieuses et tropicales, F-75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases & Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK, INSERM U.897, ISPED, Université Bordeaux, Bordeaux, France, Department of Internal Medicine University of Cologne, DE, Vanderbilt University School of Medicine, Nashville, TN, USA, National Epidemiology Center. Carlos III Health Institute, Madrid, Spain, Division of Infectious Diseases, University of Calgary, Calgary, Canada, University of Washington School of Medicine, Seattle, WA, USA, Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, USA, HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA and Johann Wolfgang Goethe-Universität, HIVCENTER, Frankfurt, Germany m.t.may@bristol.ac.uk.

International Journal of Epidemiology
|April 20, 2013
PubMed

Insights

The Antiretroviral Therapy Cohort Collaboration (ART-CC) enhances prognostic analysis for HIV-1 patients by pooling data from European and North American cohorts. This collaboration improves statistical power for studying acquired immune deficiency syndrome (AIDS) and mortality trends.

Area of Science:

  • Epidemiology
  • Virology
  • Clinical Medicine

Background:

  • Effective combination antiretroviral therapy (ART) reduced clinical events in HIV-1 patients, lowering statistical power in individual cohort studies.
  • The Antiretroviral Therapy Cohort Collaboration (ART-CC) was established in 2000 to address this by pooling data from European and North American HIV cohorts.

Purpose of the Study:

  • To study prognosis for acquired immune deficiency syndrome (AIDS) clinical events.
  • To analyze mortality in adult patients treated for HIV-1 infection.

Main Methods:

  • Data collected from 19 cohorts in Europe and North America, including over 70,000 patients who started ART before 2009.
  • Data includes demographics, HIV biomarkers (CD4 count, viral load), ART regimens, AIDS events, and causes of death.
  • Recent data collection includes co-infections (e.g., hepatitis C), risk factors (smoking, alcohol), and ART adherence.

Main Results:

  • The ART-CC database has grown significantly since its inception, encompassing a large patient population and extensive data points.
  • The collaboration facilitates robust statistical analysis for HIV prognosis and outcomes.

Conclusions:

  • The ART-CC provides a powerful resource for understanding the long-term prognosis and mortality of HIV-1 infected individuals on ART.
  • Continued collaboration and data sharing are crucial for advancing HIV research and patient care.

Keywords:
AIDSHIVantiretroviral therapycohort studyprognosis

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...